Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Study:

A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Rationale:

n/a

Purpose:

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Carcinoma, Renal Cell
Metastases, Neoplasm		 Drug: GTI-2040 Phase 1/Phase 2

Verified by Lorus Therapeutics January, 2008

Sponsored by: Lorus Therapeutics
Information provided by: Lorus Therapeutics
ClinicalTrials.gov identifier: NCT00056173

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.